Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1.
Subscribe to our email newsletter
TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
TKM-PLK1 has been shown in preclinical animal studies to selectively kill cancer cells, while sparing normal cells in healthy tissue.
The trial will recruit up to 52 patients with advanced solid tumors. Secondary objectives of the trial will be to measure tumor response as well as the pharmacodynamic effects of TKM-PLK1 in patients providing biopsies.
Tekmira Pharma president and CEO Mark Murray said TKM-PLK1 has demonstrated anti-tumor efficacy in preclinical models of liver cancer as well as tumors outside the liver, supporting our strong belief that PLK1 represents an excellent target for RNAi.
"We are excited to move forward and expect to be in a position to report interim data from the Phase 1 trial in the second half of 2011," Murray said.